U.S. District Judge Brian R. Martinotti/courtesy photo
Allergan Inc. might have struck out three times in previous efforts to enforce Latisse eyelash enhancer patents. But that doesn’t mean its fourth try, or all of them taken together, represent an illegal scheme to monopolize the $70 million-a-year market, a federal judge decided Monday.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
